Załęski, A.; Lembas, A.; Dyda, T.; Osińska, J.; Jabłońska, J.; Stempkowska-Rejek, J.; Orzechowska, J.; Wiercińska-Drapało, A.
Drug Resistance Mutations (DRMs) for Long-Acting Injectable Cabotegravir and Rilpivirine (CAB/RPV LAI) in the HIV-1 Subtype A6 Epidemic in Poland. Microorganisms 2025, 13, 321.
https://doi.org/10.3390/microorganisms13020321
AMA Style
Załęski A, Lembas A, Dyda T, Osińska J, Jabłońska J, Stempkowska-Rejek J, Orzechowska J, Wiercińska-Drapało A.
Drug Resistance Mutations (DRMs) for Long-Acting Injectable Cabotegravir and Rilpivirine (CAB/RPV LAI) in the HIV-1 Subtype A6 Epidemic in Poland. Microorganisms. 2025; 13(2):321.
https://doi.org/10.3390/microorganisms13020321
Chicago/Turabian Style
Załęski, Andrzej, Agnieszka Lembas, Tomasz Dyda, Joanna Osińska, Joanna Jabłońska, Justyna Stempkowska-Rejek, Justyna Orzechowska, and Alicja Wiercińska-Drapało.
2025. "Drug Resistance Mutations (DRMs) for Long-Acting Injectable Cabotegravir and Rilpivirine (CAB/RPV LAI) in the HIV-1 Subtype A6 Epidemic in Poland" Microorganisms 13, no. 2: 321.
https://doi.org/10.3390/microorganisms13020321
APA Style
Załęski, A., Lembas, A., Dyda, T., Osińska, J., Jabłońska, J., Stempkowska-Rejek, J., Orzechowska, J., & Wiercińska-Drapało, A.
(2025). Drug Resistance Mutations (DRMs) for Long-Acting Injectable Cabotegravir and Rilpivirine (CAB/RPV LAI) in the HIV-1 Subtype A6 Epidemic in Poland. Microorganisms, 13(2), 321.
https://doi.org/10.3390/microorganisms13020321
